Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.91% | -28.53% | 17.71% | -19.88% | 13.25% |
| Total Depreciation and Amortization | -34.42% | -84.16% | 449.72% | -1.50% | -3.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 364.80% | -37.75% | -29.99% | 18.53% | -12.97% |
| Change in Net Operating Assets | 128.86% | -253.57% | -47.58% | 408.67% | 61.60% |
| Cash from Operations | 29.98% | -149.35% | 21.47% | 23.09% | 23.39% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.13% | 0.66% | 41.65% | -24.99% | -3.27% |
| Cash from Investing | 30.13% | 0.66% | 41.76% | -25.05% | -3.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -112.00% | 64.79% | -787.50% | 88.06% | -3,250.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40,076.00% | -103.74% | 8,462.50% | 88.06% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 235.55% | -248.49% | 458.49% | 10.46% | 69.82% |